S&P 500   3,091.28 (-0.02%)
DOW   27,698.90 (+0.03%)
QQQ   201.55 (+0.00%)
CGC   18.69 (-2.96%)
BABA   183.44 (-1.89%)
GE   11.24 (-1.66%)
T   39.20 (+0.08%)
F   8.92 (-1.33%)
ACB   3.51 (-1.68%)
PRI   128.26 (-1.30%)
BAC   32.77 (-0.97%)
DIS   137.50 (-0.78%)
S&P 500   3,091.28 (-0.02%)
DOW   27,698.90 (+0.03%)
QQQ   201.55 (+0.00%)
CGC   18.69 (-2.96%)
BABA   183.44 (-1.89%)
GE   11.24 (-1.66%)
T   39.20 (+0.08%)
F   8.92 (-1.33%)
ACB   3.51 (-1.68%)
PRI   128.26 (-1.30%)
BAC   32.77 (-0.97%)
DIS   137.50 (-0.78%)
Log in

Idera Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:IDRA)

$2.07
-0.06 (-2.82 %)
(As of 11/13/2019 10:43 AM ET)
Today's Range
$2.05
Now: $2.07
$2.15
50-Day Range
$2.12
MA: $2.63
$2.94
52-Week Range
$2.02
Now: $2.07
$8.38
Volume1,800 shs
Average Volume274,569 shs
Market Capitalization$59.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IDRA
CUSIPN/A
Phone484-348-1600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$660,000.00
Book Value$2.35 per share

Profitability

Net Income$-59,880,000.00

Miscellaneous

Employees36
Market Cap$59.77 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.


Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Shares of Idera Pharmaceuticals reverse split on the morning of Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) posted its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.08. View Idera Pharmaceuticals' Earnings History.

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Idera Pharmaceuticals.

What price target have analysts set for IDRA?

3 brokerages have issued 12-month price targets for Idera Pharmaceuticals' stock. Their forecasts range from $7.00 to $14.00. On average, they expect Idera Pharmaceuticals' stock price to reach $9.33 in the next year. This suggests a possible upside of 350.9% from the stock's current price. View Analyst Price Targets for Idera Pharmaceuticals.

What is the consensus analysts' recommendation for Idera Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Idera Pharmaceuticals.

Has Idera Pharmaceuticals been receiving favorable news coverage?

News coverage about IDRA stock has trended very negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Idera Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Idera Pharmaceuticals.

Are investors shorting Idera Pharmaceuticals?

Idera Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 507,900 shares, an increase of 27.3% from the September 30th total of 399,000 shares. Based on an average trading volume of 156,300 shares, the short-interest ratio is presently 3.2 days. Approximately 2.2% of the shares of the stock are sold short. View Idera Pharmaceuticals' Current Options Chain.

Who are some of Idera Pharmaceuticals' key competitors?

What other stocks do shareholders of Idera Pharmaceuticals own?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 55)
  • Mr. John J. Kirby, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 47)
  • Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 50)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 56)
  • Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 64)

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Tower Research Capital LLC TRC (0.05%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC . Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bryant David Lim, Carol Schafer, James A Geraghty, Joanna Horobin and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $2.07.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $59.77 million and generates $660,000.00 in revenue each year. The biotechnology company earns $-59,880,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Idera Pharmaceuticals employs 36 workers across the globe.View Additional Information About Idera Pharmaceuticals.

What is Idera Pharmaceuticals' official website?

The official website for Idera Pharmaceuticals is http://www.iderapharma.com/.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]


MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel